ArticleJournal for immunotherapy of cancer2020

Correction: A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.